[
  {
    "ts": "2025-10-09T19:26:00+00:00",
    "headline": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
    "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-sell-endowment-7de1c4af?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "7dfa7479-9e55-3907-9705-0c8366cb1735",
      "content": {
        "id": "7dfa7479-9e55-3907-9705-0c8366cb1735",
        "contentType": "STORY",
        "title": "A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is.",
        "description": "",
        "summary": "A nonprofit founded by members of the Lilly family has been unloading  Eli Lilly  stock nearly every day since the start of the month.  Of the first six trading days in October, the Lilly Endowment has made sales on five of them.  The most recent transaction came on Oct. 7, when the Lilly Endowment sold 26,795 shares of common stock for an average of $848 each, or $22.7 million in total, according to a Form 4 filed with the Securities and Exchange Commission.",
        "pubDate": "2025-10-09T19:26:00Z",
        "displayTime": "2025-10-09T19:26:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7dfa7479-9e55-3907-9705-0c8366cb1735/a-major-eli-lilly-shareholder.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/522a138f4564d8135f6c9b2cf8f6e1c0",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_qLxzSrIrnSOy7n2mjjX4g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/522a138f4564d8135f6c9b2cf8f6e1c0.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KH6b285hs3af3SXfeguNNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/522a138f4564d8135f6c9b2cf8f6e1c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/eli-lilly-stock-sell-endowment-7de1c4af?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T14:57:00+00:00",
    "headline": "BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers",
    "summary": "Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.",
    "url": "https://finance.yahoo.com/news/bayry-begins-phase-study-kqb548-145700957.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4a765b14-b261-3492-a89a-309940c3853c",
      "content": {
        "id": "4a765b14-b261-3492-a89a-309940c3853c",
        "contentType": "STORY",
        "title": "BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers",
        "description": "",
        "summary": "Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.",
        "pubDate": "2025-10-09T14:57:00Z",
        "displayTime": "2025-10-09T14:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5pnU3NQ.800lSpcRBKjZNg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2_ZZ2Pl7OVNL4tXoICDoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayry-begins-phase-study-kqb548-145700957.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayry-begins-phase-study-kqb548-145700957.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T13:52:00+00:00",
    "headline": "BDTX Stock Hits 52 Week High: Is There More Room for Growth?",
    "summary": "Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.",
    "url": "https://finance.yahoo.com/news/bdtx-stock-hits-52-week-135200962.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "05515a02-db08-3e4a-bacd-2fce4352c0c7",
      "content": {
        "id": "05515a02-db08-3e4a-bacd-2fce4352c0c7",
        "contentType": "STORY",
        "title": "BDTX Stock Hits 52 Week High: Is There More Room for Growth?",
        "description": "",
        "summary": "Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.",
        "pubDate": "2025-10-09T13:52:00Z",
        "displayTime": "2025-10-09T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXyzg4eubG6sjxbQlEBpdQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7riAwjQzgy8MLH38BC1leA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b5aeac1c53d022d48463312844fb1baf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bdtx-stock-hits-52-week-135200962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bdtx-stock-hits-52-week-135200962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BDTX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T13:16:00+00:00",
    "headline": "New AI solution offers real-time peek into the mind of clinical trial participants",
    "summary": "Cognivia, an innovative AI company dedicated to helping clinical trial sponsors make smarter, more confident decisions by reducing behavioral variability, today announced the launch of its latest product, Cognivia Signal. As the world's first real-time behavioral risk intelligence dashboard, Cognivia Signal captures and displays the behavioral and contextual drivers behind trial participants. This information allows trial sponsors to instantly evaluate and assess critical information, including:",
    "url": "https://finance.yahoo.com/news/ai-solution-offers-real-time-131600264.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b3f0beb9-65b4-3149-a650-2d7d341719f6",
      "content": {
        "id": "b3f0beb9-65b4-3149-a650-2d7d341719f6",
        "contentType": "STORY",
        "title": "New AI solution offers real-time peek into the mind of clinical trial participants",
        "description": "",
        "summary": "Cognivia, an innovative AI company dedicated to helping clinical trial sponsors make smarter, more confident decisions by reducing behavioral variability, today announced the launch of its latest product, Cognivia Signal. As the world's first real-time behavioral risk intelligence dashboard, Cognivia Signal captures and displays the behavioral and contextual drivers behind trial participants. This information allows trial sponsors to instantly evaluate and assess critical information, including:",
        "pubDate": "2025-10-09T13:16:00Z",
        "displayTime": "2025-10-09T13:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/d30441a6959596934fd1194a07699df2",
          "originalWidth": 400,
          "originalHeight": 200,
          "caption": "An example of the Cognivia Signal dashboard.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gEMBJo7lOV_Kq7N7Ubw.Kg--~B/aD0yMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d30441a6959596934fd1194a07699df2.cf.webp",
              "width": 400,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fUCyqAeQcDX7w0_vOugsAw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d30441a6959596934fd1194a07699df2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ai-solution-offers-real-time-131600264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ai-solution-offers-real-time-131600264.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T13:15:01+00:00",
    "headline": "Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings",
    "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finance.yahoo.com/news/wall-streets-insights-key-metrics-131501024.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a975fa0e-3097-34db-81de-48ce6711fe53",
      "content": {
        "id": "a975fa0e-3097-34db-81de-48ce6711fe53",
        "contentType": "STORY",
        "title": "Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q3 Earnings",
        "description": "",
        "summary": "Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
        "pubDate": "2025-10-09T13:15:01Z",
        "displayTime": "2025-10-09T13:15:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
          "originalWidth": 900,
          "originalHeight": 633,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y5JgUaFZFuBLe5dh5H4ng--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 900,
              "height": 633,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IGtpvtZ0OkzJMDD0I3exBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wall-streets-insights-key-metrics-131501024.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-streets-insights-key-metrics-131501024.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T13:00:05+00:00",
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-130005181.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a9259197-40c7-3309-af42-9090b1c6cd24",
      "content": {
        "id": "a9259197-40c7-3309-af42-9090b1c6cd24",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-10-09T13:00:05Z",
        "displayTime": "2025-10-09T13:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
          "originalWidth": 900,
          "originalHeight": 618,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AH29CN1G1bp_AgmMAtiHlQ--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 900,
              "height": 618,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xcYKn6Tda5Sy52WTJQhMtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-130005181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-trending-stock-130005181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-09T02:12:41+00:00",
    "headline": "Johnson & Johnson (JNJ): Evaluating Valuation Following Recent Share Price Gains",
    "summary": "Johnson & Johnson (JNJ) shares have edged up roughly 0.4% since yesterday, continuing an upward stretch that has seen the stock climb 6% over the past month and 20% in the past three months. Investors are keeping an eye on how these steady gains reflect the company’s value position in the current market environment. See our latest analysis for Johnson & Johnson. After surging more than 30% on a share price basis year-to-date, Johnson & Johnson is showing clear momentum, even as the broader...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-evaluating-valuation-021241423.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7688a762-2396-3fad-8143-624287078187",
      "content": {
        "id": "7688a762-2396-3fad-8143-624287078187",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ): Evaluating Valuation Following Recent Share Price Gains",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) shares have edged up roughly 0.4% since yesterday, continuing an upward stretch that has seen the stock climb 6% over the past month and 20% in the past three months. Investors are keeping an eye on how these steady gains reflect the company’s value position in the current market environment. See our latest analysis for Johnson & Johnson. After surging more than 30% on a share price basis year-to-date, Johnson & Johnson is showing clear momentum, even as the broader...",
        "pubDate": "2025-10-09T02:12:41Z",
        "displayTime": "2025-10-09T02:12:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-evaluating-valuation-021241423.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-evaluating-valuation-021241423.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]